To save lives through rigorous science, data-driven decision making, and innovative medicines.


We are developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases. We have developed two unique approaches – our ImmunoPhage™ platform and our monoclonal antibody and nanobody platform. Our proprietary ImmunoPhage™ platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Our most advanced ImmunoPhage™ program, SNS-301, targets the tumor antigen, Aspartyl beta Hydroxylase (ASPH), and is in an ongoing Phase 1/2 trial in combination with pembrolizumab for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Additional programs are in various stages of preclinical development.

Located in Boston, Massachusetts and Rockville, Maryland, we have state-of-the-art laboratories for discovery, development, and manufacturing of biological products, as well as clinical testing.